Chen L, Liu F, Yoshida S, et al. Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs[J] Psychiatry Clin Neurosci, 2010, 64(5): 460-468 .
[2]
Sun Y, Vestergaard M, Christensen J, et al. Breastfeeding and risk of epilepsy in childhood: a birth cohort study[J]. J Pediatr, 2011, 158(6): 924-929.
[3]
Kazmin A, Wong RC, Sermer M, et al. Antiepileptic drugs in pregnancy and hemorrhagic disease of the newborn an update[J]. Can Fam Physician, 2010，56(12): 1291-1292.
[4]
Sabers A. Influences on seizure activity in pregnant women with epilepsy[J]. Epilepsy Behav, 2009, 15(2): 230-234.
[ 2 ] The Lancet Neurology. EURAP Signals a new era in epilepsy research[J]. Lancet Neurol, 2011, 10(7): 591.
[7]
[ 3 ] Thomas SV, Syam U, Devi JS. Predictors of seizures during pregnancy in women with epilepsy[J]. J Sucharitha Devi Epilepsia, 2012, 53(5): 85-88.
[8]
[ 4 ] Kulaga S, Sheehy O, Zargarzadeh AH，et al. Antiepileptic drug use during pregnancy: perinatal outcomes [J]. Seizure, 2011, 20(9): 667-672.
[9]
[ 5 ] Borthen I, Eide M, Daltveit A, et al. Obstetric outcome in women with epilepsy: a hospital-based, retrospective study[J]. BJOG, 2011, 118(8): 956-965.
[10]
[ 6 ] Naseer MI, Shupeng L, Kim MO. Maternal epileptic seizure induced by pentylenetetrazol: apoptotic neurodegeneration and decreased GABAB1 receptor expression in prenatal rat brain[J]. Mol Brain, 2009(2): 20.
[11]
[ 7 ] Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives[J]. Neurology, 2006, 67(12, Suppl 4): 56-58.
[12]
[ 8 ] Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs[J]. Expert Rev Neurother, 2010, 10(1): 119-140 .
[13]
[ 9 ] Ragueneau-Majlessi I, Levy RH, Janik F. Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women[J]. Epilepsia, 2002, 43(7): 697-702.
[14]
Sabers A, Christensen J. No effect of oral contraceptives on the metabolism of levetiracetam[J]. Epilepsy Res, 2011, 95(3): 277-279.
[15]
Vajda FJ, Hitchcock A, Graham J, et al. Seizure control in antiepileptic drug-treated pregnancy[J]. Epilepsia, 2008, 49(1): 172-176.
[16]
Aberd EU, Obst D, Lond RWS, et al. Folic acid metabolism and human embryopathy[J]. Lancet, 1965, 285(7398): 1254-1256.
[17]
Bauer J, B？s M, Rück J, et al. Evaluation of folate substitution in women with epilepsy. Determination of erythrocyte folic acid concentrations[J]. Der Nervenarzt, 2011, 82(4): 459-461.
[18]
Pittschieler S, Brezinka C, Jahn B, et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy[J]. J Neur, 2008, 255 (12): 1926-1931.
[19]
Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy[J]. Neurology, 2012, 78(21): 1692-1699.
[20]
Vajda FJ, Graham JE, Hitchcock AA, et al. Is lamotrigine a significant human teratogen Observations from the Australian Pregnancy Register[J]. Seizure, 2010, 19 (9): 558-561.
[21]
Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry[J]. Lancet Neurol, 2011, 10(7): 609-617.
[22]
Sabers A, Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy[J]. Epilepsia, 2009, 50(9): 2163-2166.
[23]
Sabers A. Algorithm for lamotrigine dose adjustment before, during and after pregnancy[J]. Acta Neurol Scand, 2012, 126(1): 1-4.
[24]
Ozer FD, Demirel A, Ylmaz Dilsiz O, et al. Effects of Levetiracetam on neural tube development and closure of the chick embryos in ovo[J]. Childs Nerv Syst, 2012, 28(7): 969-976.
[25]
Longo B, Forinash AB, Murphy JA. Levetiracetam use in pregnancy [J]. Ann Pharmacother, 2009, 43(10): 1692-1695.
[26]
Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures[J]. Neuropsychiatr Dis Treat, 2009(5): 467-476.
[27]
Tomson T, Palm R, K？llén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation[J]. Epilepsia, 2007, 48(6): 1111-1116.
[28]
Montouris G. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy[J]. Curr Med Res Opin, 2005, 21(5): 693-701.
[29]
Uludag S, Aydin Y, Yilmaz O. Multiple fetal anomalies in association with topiramate and oxcarbezepine treatment[J]. Fetal Pediatr Pathol, 2012, 31(3): 154-158.
[30]
Petrenaite V, Sabers A, Hansen-Schwartz J, et al. Seizure deterioration in women treated with oxcarbazepine during pregnancy[J]. Epilepsy Res, 2009, 84(2-3): 245-249.
[31]
Ohman I, Sabers A, de Flon P, et al. Pharmacokinetics of topiramate during pregnancy[J]. Epilepsy Res, 2009, 87(2-3): 124-129.
[32]
Westin AA, Nakken KO, Johannessen SI, et al. Serumconcentration/dose ratio of topiramate during pregnancy[J]. Epilepsia, 2009, 50(3): 480-485.
[33]
Prakash, Prabhu LV，Rai R, et al. Teratogenic effects of the anticonvulsant gabapentin in mice[J]. Singapore Med J, 2008, 49(1): 47-53.
[34]
Afshar M, Hassanzadeh-Taheri MM, Moallem SA, et al. Teratogenic effects of gabapentin on the skeletal system of Balb/C mice fetuses[J]. Neurosciences (Riyadh), 2009, 14(3): 239-244.
[35]
Ozkan H, Cetinkaya M, K？ksal N, et al. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly[J]. J Matern Fetal Neonatal Med, 2011, 24(3): 521-524.
[36]
Meador KJ, Baker GA, Browning N, et al. Effects of breastfeeding in children of women taking antiepileptic drugs[J]. Neurology, 2010, 75(22): 1954-1960.
